We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+21.62%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$135M
AUM Growth
+$7.99M
Cap. Flow
+$4.82M
Cap. Flow %
3.56%
Top 10 Hldgs %
69.24%
Holding
34
New
11
Increased
8
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$17.7M
2
CMRX
Chimerix, Inc.
CMRX
+$10.8M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$5.41M
4
BIND
BIND THERAPEUTICS INC
BIND
+$3.55M
5
EPZM
Epizyme, Inc
EPZM
+$3.5M

Top Sells

Rank Stock Value
1
GENT
GENTIUM SPA ADS
GENT
+$29.2M
2
GERN icon
Geron
GERN
+$6.5M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$3.67M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.64M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$1.9M

Sector Composition

Rank Sector Weight
1 Healthcare 80.23%
2 Miscellaneous 19.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
1
Travere Therapeutics
TVTX
$6.36B
$24.4M 18.06%
+1,153,230
New +$17.7M
ARIA
2
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$13.5M 9.94%
1,670,000
– –
CMRX
3
DELISTED
Chimerix, Inc.
CMRX
$12.2M 9.04%
+536,000
New +$10.8M
PCYC
4
DELISTED
PHARMACYCLICS INC
PCYC
$11.5M 8.51%
115,000
-5,000
-4% -$650K
NSPR icon
5
InspireMD
NSPR
$41.6M
– –
0
– –
OMER icon
6
Omeros
OMER
$1.39B
$6.04M 4.46%
500,100
+40,100
+9% +$493K
CEMP
7
DELISTED
Cempra, Inc.
CEMP
$5.54M 4.1%
480,000
+115,000
+32% +$1.43M
BIND
8
DELISTED
BIND THERAPEUTICS INC
BIND
$5.11M 3.77%
427,000
+272,000
+175% +$3.55M
NPSP
9
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$4.49M 3.32%
150,000
-55,000
-27% -$1.9M
GNMK
10
DELISTED
GenMark Diagnostics, Inc
GNMK
$4.32M 3.19%
+435,000
New +$5.41M
CSII
11
DELISTED
Cardiovascular Systems, Inc.
CSII
$4.29M 3.17%
135,000
– –
NVDQ
12
DELISTED
Novadaq Technologies Inc.
NVDQ
$4.12M 3.04%
167,600
– –
LAB icon
13
Standard BioTools
LAB
$256M
$3.97M 2.93%
90,000
-42,500
-32% -$1.87M
BLRX
14
BioLineRX
BLRX
$12.1M
$3.24M 2.39%
2,418
+1,230
+104% +$2.02M
CPRX
15
DELISTED
Catalyst Pharmaceutical
CPRX
$3.12M 2.3%
1,378,584
+24,684
+2% +$51.6K
EPZM
16
DELISTED
Epizyme, Inc
EPZM
$2.63M 1.94%
+115,500
New +$3.5M
LGND icon
17
Ligand Pharmaceuticals
LGND
$5.67B
$2.35M 1.74%
56,105
-88,165
-61% -$3.67M
GERN icon
18
Geron
GERN
$983M
$2.3M 1.7%
1,163,800
-1,629,320
-58% -$6.5M
FLXN
19
DELISTED
Flexion Therapeutics, Inc.
FLXN
$2.23M 1.65%
+135,500
New +$2.34M
EVOK
20
DELISTED
Evoke Pharma
EVOK
$1.96M 1.44%
+1,621
New +$2.31M
CELGZ
21
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$1.88M 1.39%
660,000
-140,000
-18% -$423K
TTPH
22
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.76M 1.3%
8,000
+325
+4% +$90.6K
KBIO
23
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$1.47M 1.09%
68,125
+32,500
+91% +$942K
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
$1.43M 1.06%
+305,000
New +$1.53M
CDXS icon
25
Codexis
CDXS
$182M
$1.43M 1.05%
+698,300
New +$1.27M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2014 Portfolio in Review

As of Q1 2014, Opaleye Management held 34 positions worth $135M, up 6.3% from $127M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Opaleye Management deployed $4.82M of net new capital in Q1 2014, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Travere Therapeutics: 1,153,230 shares worth $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 56% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Geron, an estimated $6.5M trimmed.

  • Opaleye Management's largest Q1 2014 buy was Travere Therapeutics: 1,153,230 shares worth $24.4M.
  • Opaleye Management added most to BIND THERAPEUTICS INC in Q1 2014, an estimated $3.55M increase.
  • Opaleye Management's biggest Q1 2014 reduction was Geron, cutting an estimated $6.5M.
  • Opaleye Management fully exited GENTIUM SPA ADS in Q1 2014, selling an estimated $29.2M.
  • Opaleye Management's ten largest holdings make up 69% of its $135M portfolio in Q1 2014.
  • Opaleye Management opened 11 new positions and closed 4 in Q1 2014.
  • Opaleye Management's portfolio value rose 6.3% quarter-over-quarter to $135M.

Based on Opaleye Management's 13F filing for Q1 2014, filed 15 May 2014.